$2.43 Billion is the total value of Deep Track Capital, LP's 58 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $92,055,000 | – | 1,700,000 | +100.0% | 3.78% | – |
| ALKS | New | ALKERMES PLC | $84,570,000 | – | 3,000,000 | +100.0% | 3.47% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $66,280,680 | – | 729,000 | +100.0% | 2.72% | – |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $62,966,936 | – | 2,646,782 | +100.0% | 2.59% | – | |
| SGEN | New | SEAGEN INCput | $44,097,966 | – | 217,800 | +100.0% | 1.81% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $40,580,836 | – | 3,504,390 | +100.0% | 1.67% | – |
| EXEL | New | EXELIXIS INC | $37,497,674 | – | 1,931,874 | +100.0% | 1.54% | – |
| ARGX | New | ARGENX SEput | $37,258,000 | – | 100,000 | +100.0% | 1.53% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $21,061,455 | – | 1,363,201 | +100.0% | 0.86% | – |
| QURE | New | UNIQURE NV | $17,436,547 | – | 865,767 | +100.0% | 0.72% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $17,048,681 | – | 2,345,073 | +100.0% | 0.70% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $13,825,575 | – | 1,708,971 | +100.0% | 0.57% | – |
| New | ORCHARD THERAPEUTICS PLCspon ads new | $6,265,018 | – | 1,166,670 | +100.0% | 0.26% | – | |
| IMUX | New | IMMUNIC INC | $3,761,121 | – | 2,524,242 | +100.0% | 0.15% | – |
| New | 2SEVENTY BIO INC | $3,570,000 | – | 350,000 | +100.0% | 0.15% | – | |
| IMGN | New | IMMUNOGEN INCput | $1,643,904 | – | 428,100 | +100.0% | 0.07% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $1,225,329 | – | 1,743,248 | +100.0% | 0.05% | – |
| ETNB | New | 89BIO INCput | $67,012 | – | 4,400 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
| IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
| BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
| BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
| 4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
| REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
| ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
| Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
| CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
| Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
| KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-26 |
| SC 13G | 2024-04-26 |
| SC 13G/A | 2024-04-22 |
| SC 13G | 2024-04-12 |
| SC 13G | 2024-04-05 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-15 |
| 3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.